Name: Han Ju
M/F: Male
Date of Birth: October 30th, 1993
Nationality: P. R. China
Address: State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Xue Yuan Road 38, Beijing 100191, China
Phone: (+86)-17865158937
E-mail: 1652290797@qq.com
Educational Background
2023 - now： Postdoctoral Fellow
Major: Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University.
09.2018-06.2022: Ph.D.
Major: Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University
Supervisor: Prof. Xinyong Liu.
09.2015 -06.2018: M.S.
Major: Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University
Supervisor: Prof. Xinyong Liu.
09.2011 - 07.2015: Bachelor of Science
Major: Pharmaceutical Engineering, Shenyang Pharmaceutical University.
Publication List
1. Identification of C5-NH2 modified oseltamivir derivatives as novel influenza neuraminidase inhibitors with highly improved antiviral activities and favorable druggability（2021，Journal of Medicinal Chemistry，第一作者）
2. Iterative Optimization and Structure-Activity Relationship Studies of Oseltamivir Amino Derivatives as Potent and Selective Neuraminidase Inhibitors via Targeting 150-cavity（2022，Journal of Medicinal Chemistry，共第一1/2）
3. Discovery of ligustrazine and chalcone derivatives as novel viral nucleoprotein nuclear export inhibitors against influenza viruses（2023，Journal of Medical Virology，共第一2/3）
4. Inhibitors of influenza virus polymerase acidic (PA) endonuclease: contemporary developments and perspectives（2017，Journal of Medicinal Chemistry，第一作者）
5. Discovery of novel 1,2,3-triazole oseltamivir derivatives as potent influenza neuraminidase inhibitors targeting the 430-cavity（2019，European Journal of Medicinal Chemistry，第一作者）
6. Discovery of C-1 modified oseltamivir derivatives as potent influenza neuraminidase inhibitors （2018，European Journal of Medicinal Chemistry，第一作者）
7. Contemporary medicinal chemistry strategies for the discovery and optimization of anti-influenza inhibitors targeting vRNP constituent proteins（2021，Acta Pharmaceutica Sinica B，共第一3/3）
8. Designing influenza polymerase acidic endonuclease inhibitors via 'privileged scaffold' re-evolution/refining strategy（2019，Future Medicinal Chemistry,第一作者）